Gemcitabine-cisplatin-vinorelbine phase II trial in stage III non small cell lung cancer

Cueva, J; Grande, Carlos; Firvida, J.L.; Amenedo, Margarita; Romero, C.; Quintero, Guillermo; Huidobro, G.; Garcı́a, Juan Carlos; Baron, F.

doi:10.1016/s0959-8049(99)81449-x

European Journal of Cancer

1999

DOI: 10.1016/s0959-8049(99)81449-x

|View full text |Cite

Gemcitabine-cisplatin-vinorelbine phase II trial in stage III non small cell lung cancer

J Cueva¹,

Carlos Grande²,

J.L. Firvida³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2002

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Objective responses (ORs) were observed in 53% of the cases., with no complete responses (CRs)., and 8 patients were resected. Cueva et al[68] assessed a threedrug combination including cisplatin., vinorelbine and gemcitabine on 46 stage IIIA/IIIB patients. They observed 62% of ORs (CRs 5%) with 15% of the patients radically operated on.…”

mentioning

confidence: 99%

Vinorelbine in the Treatment of Non-Small Cell Lung Cancer

Gridelli¹,

Vivo

2002

CMC

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) remains a fatal disease: the majority of patients are diagnosed as having metastases or advanced inoperable tumors. The activity of chemotherapy in NSCLC patients is low with objective response rarely complete and sustained. Cisplatin-based combinations are considered as the standard chemotherapy treatment. Recently., the introduction of new and less toxic chemotherapeutic agents., such as vinorelbine., has led investigators to research for active non-cisplatin-containing combinations to treat patients with advanced disease having as primary needs symptom relief and an acceptable quality of life. This review will focus on the pharmacological properties of vinorelbine and its role in adjuvant chemotherapy., in combined chemo-radiotherapy., in advanced disease and in the particular setting of the elderly. The oral use of vinorelbine will be among the future developments of this drug.

show abstract

mentioning

confidence: 99%

Vinorelbine in the Treatment of Non-Small Cell Lung Cancer

Gridelli¹,

Vivo

2002

CMC

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Gemcitabine-cisplatin-vinorelbine phase II trial in stage III non small cell lung cancer

Cited by 1 publication

References 0 publications

Vinorelbine in the Treatment of Non-Small Cell Lung Cancer

Vinorelbine in the Treatment of Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About